ZLN005 is a benzimidazole derivative primarily investigated for its pharmacological potential as a selective serotonin and dopamine reuptake inhibitor, with applications explored in research contexts involving… Read more









ZLN005 is a benzimidazole derivative primarily investigated for its pharmacological potential as a selective serotonin and dopamine reuptake inhibitor, with applications explored in research contexts involving major depressive disorder and obsessive-compulsive disorder. To support rigorous pharmaceutical analysis, this category provides a comprehensive selection of high-quality reference standards, including synthesized metabolites like 5-hydroxy-ZLN005 and various stable isotope-labelled compounds. Pharmaceutical and clinical laboratories utilize these compounds as internal standards during mass spectrometry and chromatographic analysis to ensure accurate quantification and impurity profiling. By incorporating these labelled analogues and specific metabolic markers into their workflows, researchers can effectively validate analytical methods, confirm structural integrity, and maintain strict quality control standards throughout the development and testing process.